DF Dent & Co. Inc. Sells 14,151 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

DF Dent & Co. Inc. trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 147,147 shares of the company’s stock after selling 14,151 shares during the quarter. DF Dent & Co. Inc. owned 0.47% of Medpace worth $48,887,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of MEDP. Lindbrook Capital LLC increased its holdings in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC grew its position in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock worth $1,789,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. increased its stake in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after buying an additional 29 shares during the period. Proficio Capital Partners LLC raised its holdings in shares of Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after acquiring an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. lifted its stake in Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after acquiring an additional 30 shares during the period. 77.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective on the stock. Finally, Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $376.30.

Medpace Trading Up 4.5 %

NASDAQ MEDP opened at $311.23 on Thursday. Medpace Holdings, Inc. has a 12 month low of $289.01 and a 12 month high of $459.77. The stock’s fifty day moving average price is $333.58 and its 200-day moving average price is $338.33. The stock has a market cap of $9.48 billion, a P/E ratio of 24.64, a P/E/G ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.